Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis and Demand Forecast to 2025
The global programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors market is valued at an estimated $4,926.4 million in 2016, and it is expected to grow at a CAGR of 23.4% during 2017 - 2025.
The growth of the global market is largely driven by the increased investment and funding, strong pipeline, and improved safety and efficacy. BGB-A317, a Phase I therapeutic candidate of BeiGene Ltd., gained $75 million funding to continued development of targeted oncology candidate. PD-1 and PD-L1 inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer, melanoma and others. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer, and yield a good response rate of any single-agent immunotherapy. This creates huge traction in pharmaceutical industry to develop PD-1 and PD-L1 inhibitors for treatment of different types of cancer.
Explore Report with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market
PD-1 and PD-L1 inhibitors are highly growing immunotherapies that are being used in oncology therapy area. The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs and there are approximately 245 active clinical studies. Currently, durvalumab from Astrazeneca and atezolizumab from Roche are among the most promising molecules in the pipeline, in terms of efficacy and safety. These molecules are in Phase III stage and expected to be launched in the coming years for the treatment of non-small cell lung cancer. There are many drugs in early stage of pipeline; thus, making PD1 and PDL1 inhibitors market very lucrative.
Among the different marketed PD-1 and PD-L1 inhibitor drugs, the largest revenue globally was generated from the sale of Opdivo in 2016. The global demand of Tecentriq is expected to witness high growth, primarily driven by the lack of approved competitor PD-L1 inhibitors drugs and high prevalence of urothelioma cancer.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market/report-sample
Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Merck KGaA.
